From January 2012 to October 2019, 3562 patients were diagnosed with lung cancer, and 812 patients with stage IIIB–IV lung adenocarcinoma received EGFR‐TKI as first‐line therapy. This evidence concerns the gene EGFR and lung adenocarcinoma.